Replaces Prod. #: BML-GR356
A potent platinum-based antineoplastic drug. Its mode of action involves formation of inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. Platinated DNA adducts also enhance poisoning of DNA topoisomerase I. Cisplatin synergizes with a variety of anticancer agents. Tumor cells rapidly develop resistance to cisplatin and numerous agents are available to block or reverse resistance.
Product Details
| Alternative Name: | cis-Platinum(ll)diamine dichloride |
| |
| Formula: | Cl2H6N2Pt |
| |
| MW: | 300.0 |
| |
| CAS: | 15663-27-1 |
| |
| MI: | 14: 2317 |
| |
| RTECS: | TP2450000 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | Off-white to orange powder. |
| |
| Solubility: | Soluble in dimethyl formamide (16mg/ml) or DMSO (10mg/ml); sparingly soluble in water; insoluble in 100% ethanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Handling: | Protect from light. |
| |
| Technical Info/Product Notes: | In aqueous solution cis-trans isomerization of cisplatin occurs. Isomerization is increased at elevated temperatures. Stability of cisplatin in aqueous solutions was enhanced by increasing the sodium chloride (NaCl) concentration to 0.9% and was adversely affected in alkaline solutions such as sodium bicarbonate solutions. Further, even though soluble in DMSO we do not recommend to dissolve cisplatin in DMSO. The DMSO inserts itself into the ligand. It is recommended to prepare all solutions fresh and protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Malaria-driven expansion of adaptive-like functional CD56-negative NK cells correlates with clinical immunity to malaria: M. Ty, et al.; Sci. Transl. Med.
15, eadd9012 (2023),
Abstract;
Mass-Cytometry-Based Quantification of Global Histone Post-Translational Modifications at Single-Cell Resolution Across Peripheral Immune Cells in IBD: L. Bai, et al.; J. Crohns Colitis
17, 804 (2022),
Abstract;
Relative refractoriness of breast cancer cells to tumour necrosis factor-α induced necroptosis: B. Thakur, et al.; Clin. Exp. Pharmacol. Physiol.
49, 1294 (2022),
Abstract;
A selective p53 activator and anticancer agent to improve colorectal cancer therapy: H. Ramos, et al.; Cell Rep.
35, 10892 (2021),
Abstract;
Autophagy displays divergent roles during intermittent amino acid starvation and toxic stress-induced senescence in cultured skeletal muscle cells: D. Bloemberg & J. Quadilatero; J. Cell. Physiol.
236, 3099 (2021),
Application(s): Mouse skeletal myoblasts (C2C12) treatment,
Abstract;
The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination: F. Wimmers, et al.; Cell
184, 3915 (2021),
Abstract;
Full Text
Natural killer cell phenotype is altered in HIV-exposed seronegative women: N.Q. Zhao, et al.; PLoS One
15, e0238347 (2020),
Abstract;
Full Text
Single cell immune profiling of dengue virus patients reveals intact immune responses to Zika virus with enrichment of innate immune signatures: Y. Zhao, et al.; PLoS Negl. Trop. Dis.
14, e0008112 (2020),
Abstract;
SATB1 and bladder cancer: Is there a functional link?: D. Choudhary, et al.; Urol. Oncol.
36, 93.e13 (2018),
Abstract;
Aldehyde dehydrogenase 2*2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment: J. Kim, et al.; J. Biomed. Sci.
24, 33 (2017),
Abstract;
Full Text
Synthesis and characterization of a new alkyne functionalized bis(pyrazolyl)methane ligand and of its Pd(II) complexes: Evaluation of their in vitro cytotoxic activity: C. Di Nicola, et al.; Inorganica Chim. Acta 455, 677 (2017), Application(s): Cell culture,
Caspase activity and apoptotic signaling in proliferating C2C12 cells following cisplatin or A23187 exposure: D. Bloemberg, et al.; Data Brief 7, 1024 (2016), Application(s): Cell culture,
Exploiting Synthetic Lethality in Ovarian Cancer: R.L. O'Donnell; (2016), (PhD thesis),
Full Text
MicroRNA-Based Methods and Assays for Osteosarcoma: T. Ochiya, et al.; (2016), (U. S. Patent),
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673: A.Z. Andrei, et al.; Cancer Lett.
364, 8 (2015),
Application(s): Cell Culture,
Abstract;
Single Cell Mass Cytometry Reveals Remodeling of Human T Cell Phenotypes by Varicella Zoster Virus: N. Sen, et al.; Methods
90, 85 (2015),
Application(s): Cell Culture,
Abstract;
Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin: S. Strieth, et al.; Clin. Cancer Res.
14, 4603 (2008),
Abstract;
Protein kinase C inhibitor Go6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model: L. Qamar, et al.; Gynecol. Oncol.
110, 425 (2008),
Abstract;
Effectiveness of hsp90 inhibitors as anti-cancer drugs: L. Xiao, et al.; Mini Rev. Med. Chem.
6, 1137 (2006), (Review),
Abstract;
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin: R.C. van Waardenburg et al.; J. Biol. Chem.
279, 54502 (2004),
Abstract;
Cisplatin: mode of cytotoxic action and molecular basis of resistance: Z.H. Siddik ; Oncogene
22, 7265 (2003),
Abstract;
Biomolecular targets for platinum antitumor drugs: R.N. Bose ; Mini Rev. Med. Chem.
2, 103 (2002),
Abstract;
Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma: K. Seki, et al.; Cancer Chemother. Pharmacol.
45, 199 (2000),
Abstract;
Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system: M.S. Razzaque, et al.; Histochem. Cell Biol.
111, 359 (1999),
Abstract;
Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin: J. Melendez-Zajgla, et al.; Biochem. Mol. Biol. Int.
47, 765 (1999),
Abstract;
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage: J.G. Gong, et al.; Nature
399, 806 (1999),
Abstract;
Cisplatin induces a persistent activation of JNK that is related to cell death: I. Sanchez-Perez, et al.; Oncogene
16, 533 (1998),
Abstract;
Telomere loss in cells treated with cisplatin: T. Ishibashi & S.J. Lippard; PNAS
95, 4219 (1998),
Abstract;
